Zynerba Pharma (ZYNE): Reiterating Overweight After Earnings and Ahead of Potential Catalysts - Piper Jaffray

August 12, 2016 7:48 AM EDT
Get Alerts ZYNE Hot Sheet
Price: $14.46 +9.71%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 28
Trade ZYNE Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) in advance of anticipated 2H16 program progress, and trial starts to enable 1H17 clinical-stage data on ZYN-002 and ZYN-001.

On 8/11, ZYNE reported 2Q16 earnings, ending the quarter with $32.1M in cash. The analyst projects current cash can fund operations through mid’17, inclusive of Phase II results from the now enrolling STAR 1 study in adult epilepsy, as well as results from planned studies in OA and FX. The analyst is supportive of STAR 1 and believes a CBD transdermal has potential to provide significant clinical benefit in terms of seizure reduction combined with a convenient formulation and a low-burden side effect profile.

That said, he is also intrigued by less conventional indications for CBD, such as FX, and will look for trial design details and POC data in the next 12 months to shape his view on broad applicability of this platform. In advance of anticipated 2H16 program progress, and trial starts, to enable 1H17 clinical-stage data on ZYN-002 and ZYN-001.

No change to the price target of $42.

For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.

Shares of Zynerba Pharmaceuticals closed at $9.91 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray, Earnings, Charles Duncan

Add Your Comment